The impact of Girdin expression on recurrence-free survival in patients with luminal-type breast cancer

详细信息    查看全文

• 作者：Kazumi Nishimae ; Nobuyuki Tsunoda ; Yukihiro Yokoyama ; Toshio Kokuryo…
• 关键词：Breast cancer ; Girdin ; Luminal type ; Lymph node metastasis ; Chemotherapy
• 刊名：Breast Cancer
• 出版年：2015
• 出版时间：September 2015
• 年：2015
• 卷：22
• 期：5
• 页码：445-451
• 全文大小：827 KB
• 参考文献：1.Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes鈥攄ealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011;22(8):1736鈥?7.PubMed CrossRef PubMed Central
  2.Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005;23(28):7212鈥?0.PubMed CrossRef
  3.Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol. 2005;16(11):1723鈥?9.PubMed CrossRef
  4.Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Can. 2002;2(7):489鈥?01.CrossRef
  5.Kane LP, Shapiro VS, Stokoe D, Weiss A. Induction of NF-kappaB by the Akt/PKB kinase. Curr Biol CB. 1999;9(11):601鈥?.PubMed CrossRef
  6.Kops GJ, de Ruiter ND, De Vries-Smits AM, Powell DR, Bos JL, Burgering BM. Direct control of the Fork head transcription factor AFX by protein kinase B. Nature. 1999;398(6728):630鈥?.PubMed CrossRef
  7.Hutchinson J, Jin J, Cardiff RD, Woodgett JR, Muller WJ. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol. 2001;21(6):2203鈥?2.PubMed CrossRef PubMed Central
  8.Enomoto A, Murakami H, Asai N, Morone N, Watanabe T, Kawai K, et al. Akt/PKB regulates actin organization and cell motility via Girdin/APE. Dev Cell. 2005;9(3):389鈥?02.PubMed CrossRef
  9.Jiang P, Enomoto A, Jijiwa M, Kato T, Hasegawa T, Ishida M, et al. An actin-binding protein Girdin regulates the motility of breast cancer cells. Can Res. 2008;68(5):1310鈥?.CrossRef
  10.Liu C, Zhang Y, Xu H, Zhang R, Li H, Lu P, et al. Girdin protein: a new potential distant metastasis predictor of breast cancer. Med Oncol. 2012;29(3):1554鈥?0.PubMed CrossRef
  11.Ling Y, Jiang P, Cui SP, Ren YL, Zhu SN, Yang JP, et al. Clinical implications for girdin protein expression in breast cancer. Can Inv. 2011;29(6):405鈥?0.CrossRef
  12.Dowsett M, Nielsen TO, A鈥橦ern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Can Inst. 2011;103(22):1656鈥?4.CrossRef
  13.Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Can Inst. 2009;101(10):736鈥?0.CrossRef
  14.Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11(2):155鈥?8.PubMed
  15.Badve S, Nakshatri H. Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. J Clin Pathol. 2009;62(1):6鈥?2.PubMed CrossRef
  16.Kroger N, Milde-Langosch K, Riethdorf S, Schmoor C, Schumacher M, Zander AR, et al. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Can Res. 2006;12(1):159鈥?8.CrossRef
  17.Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Can Res Treat. 2008;107(3):309鈥?0.CrossRef
  
• 作者单位：Kazumi Nishimae (1)
  Nobuyuki Tsunoda (1)
  Yukihiro Yokoyama (1)
  Toshio Kokuryo (1)
  Akari Iwakoshi (2)
  Masahide Takahashi (2)
  Masato Nagino (1)
  
  1. Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
  2. Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan
  
• 刊物主题：Surgical Oncology; Oncology; Surgery; Cancer Research;
• 出版者：Springer Japan
• ISSN：1880-4233

文摘

Background In patients with luminal-type breast cancer (positive for ER and/or PgR), a complete consensus on the threshold indication for a combination of chemotherapy and endocrine therapy has not been achieved, especially for patients with HER2-negative luminal type (HNLT). Girdin, an actin-binding Akt substrate, plays a crucial role in the migration of cancer cells. This study examined the expression of Girdin in relation to clinicopathological features and other immunohistochemical markers (HER2, Ki-67), especially in patients with HNLT breast cancer.